{"id":"eicosapentaenoic-acid-gastro-resistant-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Fishy aftertaste"},{"rate":null,"effect":"Bleeding risk (at high doses)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EPA is incorporated into cell membranes and acts as a substrate for the production of anti-inflammatory eicosanoids, reducing triglyceride synthesis in the liver and decreasing circulating triglyceride levels. The gastro-resistant formulation protects the active ingredient from degradation in the stomach, allowing targeted delivery to the small intestine for optimal absorption. This mechanism helps reduce cardiovascular risk in patients with elevated triglycerides.","oneSentence":"Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that reduces triglycerides and modulates inflammatory pathways in cardiovascular disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:13.997Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertriglyceridemia (elevated triglycerides)"},{"name":"Cardiovascular risk reduction in patients with elevated triglycerides"}]},"trialDetails":[{"nctId":"NCT03806426","phase":"PHASE3","title":"Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis","status":"ACTIVE_NOT_RECRUITING","sponsor":"S.L.A. Pharma AG","startDate":"2018-12-05","conditions":"Familial Adenomatous Polyposis","enrollment":204},{"nctId":"NCT04335032","phase":"PHASE3","title":"EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)","status":"UNKNOWN","sponsor":"S.L.A. Pharma AG","startDate":"2021-01-08","conditions":"SARS-CoV-2","enrollment":284}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Alfa"],"phase":"phase_3","status":"active","brandName":"Eicosapentaenoic acid gastro-resistant capsules","genericName":"Eicosapentaenoic acid gastro-resistant capsules","companyName":"S.L.A. Pharma AG","companyId":"s-l-a-pharma-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that reduces triglycerides and modulates inflammatory pathways in cardiovascular disease. Used for Hypertriglyceridemia (elevated triglycerides), Cardiovascular risk reduction in patients with elevated triglycerides.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}